JOINT VENTURE AND LICENSE OPTION AGREEMENTConfidential Treatment • November 14th, 2012 • Tg Therapeutics, Inc. • Pharmaceutical preparations • New York
This JOINT VENTURE AND LICENSE OPTION AGREEMENT (the “Agreement”) is entered into on August 15, 2012 (the “Effective Date”) between Rhizen Pharmaceuticals S A, a company incorporated under the laws of Switzerland, with a place of business at Fritz-Courvoisier 40, CH-2300 La Chaux-de-Fonds, Switzerland (“Rhizen”), and TG Therapeutics, Inc., a Delaware corporation, with a place of business at 787 Seventh Avenue, New York, NY (“TGTX”). Rhizen and TGTX are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
